A longitudinal study of relation between side-effects and clinical improvement in schizophrenia: Is there a Neuro-Metabolic threshold for second generation antipsychotics?

Clinical Psychopharmacology and Neuroscience

Volumn 11, Issue 1, 2013, Pages 24-27

  Venkatasubramanian, Ganesan ^a   Rao, Naren P ^a   Arasappa, Rashmi ^a   Kalmady, Sunil V ^a   Gangadhar, Bangalore N ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Antipsychotic; Extrapyramidal; Insulin; Metabolic; Schizophrenia

Indexed keywords

SECOND GENERATION ANTIPSYCHOTIC AGENT; TRANQUILIZER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFICACY; DRUG SAFETY; DSM-IV; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; PROSPECTIVE STUDY; SCALE FOR ASSESSMENT OF NEGATIVE SYMPTOM; SCALE FOR ASSESSMENT OF POSITIVE SYMPTOMS; SCHIZOPHRENIA; SIMPSON ANGUS EXTRA PYRAMIDAL SCALE; TREATMENT OUTCOME;

EID: 84876904216     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2013.11.1.24     Document Type: Article

References (21)

1. Bitter I, Volavka J, Scheurer J. The concept of the neuroleptic threshold: an update. J Clin Psychopharmacol 1991;11:28-33.
2. McEvoy JP. The neuroleptic threshold as a marker of minimum effective neuroleptic dose. Compr Psychiatry 1986;27:327-335. (Pubitemid 16077928)
3. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D (2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-520. (Pubitemid 30191189)
4. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-235. (Pubitemid 23091497)
5. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-544.
6. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009;119:171-179.
7. Bustillo JR, Buchanan RW, Irish D, Breier A. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 1996;153:817-819. (Pubitemid 26170545)
8. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992;149:68-72.
9. Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 2003;59:19-27. (Pubitemid 35291087)
10. Czobor P, Volavka J, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002;22:244-251. (Pubitemid 34546838)
11. Gupta S, Droney T, Al-Samarrai S, Keller P, Frank B. Olanzapine: weight gain and therapeutic efficacy. J Clin Psychopharmacol 1999;19:273-275.
12. Jones B, Basson BR, Walker DJ, Crawford AM, Kinon BJ. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 2001;62(Suppl 2):41-44. (Pubitemid 32154141)
13. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001;62:231-238. (Pubitemid 32428761)
14. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M. I. N. I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):22-33. (Pubitemid 29001829)
15. Andreasen NC. The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: University of Iowa; 1984.
16. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa; 1983.
17. Mohan V, Deepa R, Deepa M, Somannavar S, Datta M. A simplified Indian Diabetes Risk Score for screening for undiagnosed diabetic subjects. J Assoc Physicians India 2005;53:759-763. (Pubitemid 41365556)
18. Girgis RR, Javitch JA, Lieberman JA. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol Psychiatry 2008;13:918-929.
19. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284-289. (Pubitemid 41110453)
20. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989;1:495. (Pubitemid 19063553)
21. Venkatasubramanian G, Chittiprol S, Neelakantachar N, Naveen MN, Thirthall J, Gangadhar BN, et al. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 2007;164:1557-1560. (Pubitemid 350069735)